linvoseltamab-gcpt (Lynozyfic)
linvoseltamab-gcpt is an FDA-licensed reference biologic from Regeneron Pharmaceuticals, Inc.. Reference exclusivity, biosimilar lineage, and published patents from official FDA Purple Book records.
0
Biosimilars
0
Interchangeables
0
Listed patents
2025
Reference approved
Reference product
Lynozyfic linvoseltamab-gcpt
Regeneron Pharmaceuticals, Inc.
- Approved
- Jul 02, 2025
- Marketing
- Rx
- Center
- CDER
- Patents
- None listed
Exclusivity & patent cliffs
Approval, exclusivity, and published-patent expiration dates for linvoseltamab-gcpt, in chronological order.
Reference approval
Approval date of the reference linvoseltamab-gcpt product.
11 mo ago
Frequently asked questions
Are there biosimilars approved for linvoseltamab-gcpt (Lynozyfic)?
No 351(k) biosimilars or interchangeable biosimilars referencing linvoseltamab-gcpt are listed in the FDA Purple Book yet.
Explore the full FDA Purple Book
Search every FDA-licensed biologic, biosimilar, and interchangeable with exclusivity timelines and patent records.